Impedimed Ltd (AU:IPD) — Market Cap & Net Worth
Market Cap & Net Worth: Impedimed Ltd (IPD)
Impedimed Ltd (AU:IPD) has a market capitalization of $12.96 Million (AU$18.31 Million) as of September 20, 2026. Listed on the AU stock exchange, this Australia-based company holds position #26479 globally and #1208 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Impedimed Ltd's stock price AU$0.01 by its total outstanding shares 3662493691 (3.66 Billion). Also see how large is Impedimed Ltd's balance sheet for a full breakdown of the balance sheet.
Impedimed Ltd Market Cap History: 2015 to 2026
Impedimed Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.92 Billion to $12.96 Million (-37.69% CAGR). Also see Impedimed Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Impedimed Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Impedimed Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Impedimed Ltd (IPD) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.89x
Impedimed Ltd's market cap is 0.89 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $2.51 Billion | $5.77 Million | -$27.57 Million | 435.28x | N/A |
| 2018 | $469.83 Million | $3.32 Million | -$27.25 Million | 141.60x | N/A |
| 2019 | $412.56 Million | $4.16 Million | -$24.00 Million | 99.27x | N/A |
| 2020 | $323.93 Million | $5.74 Million | -$21.38 Million | 56.42x | N/A |
| 2021 | $453.50 Million | $8.41 Million | -$20.71 Million | 53.93x | N/A |
| 2022 | $204.72 Million | $10.57 Million | -$19.87 Million | 19.38x | N/A |
| 2023 | $375.76 Million | $11.34 Million | -$20.52 Million | 33.12x | N/A |
| 2024 | $134.76 Million | $10.32 Million | -$19.79 Million | 13.06x | N/A |
| 2025 | $88.11 Million | $12.72 Million | -$23.24 Million | 6.92x | N/A |
| 2026 | $12.96 Million | $14.61 Million | -$24.91 Million | 0.89x | N/A |
Competitor Companies of IPD by Market Capitalization
Companies near Impedimed Ltd in the global market cap rankings as of September 20, 2026. Review tangible net worth ratio of Impedimed Ltd to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Impedimed Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #124 globally with a market cap of $178.43 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #238 globally with a market cap of $105.53 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #124 | Abbott Laboratories | NYSE:ABT | $178.43 Billion | $102.61 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.13 |
| #238 | Stryker Corporation | NYSE:SYK | $105.53 Billion | $275.12 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Impedimed Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Impedimed Ltd's market cap moved from $2.92 Billion to $ 12.96 Million, with a yearly change of -37.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$12.96 Million | -85.29% |
| 2025 | AU$88.11 Million | -34.62% |
| 2024 | AU$134.76 Million | -64.14% |
| 2023 | AU$375.76 Million | +83.54% |
| 2022 | AU$204.72 Million | -54.86% |
| 2021 | AU$453.50 Million | +40.00% |
| 2020 | AU$323.93 Million | -21.48% |
| 2019 | AU$412.56 Million | -12.19% |
| 2018 | AU$469.83 Million | -81.28% |
| 2017 | AU$2.51 Billion | -1.46% |
| 2016 | AU$2.55 Billion | -12.71% |
| 2015 | AU$2.92 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Impedimed Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.96 Million USD |
| MoneyControl | $12.96 Million USD |
| MarketWatch | $12.96 Million USD |
| marketcap.company | $12.96 Million USD |
| Reuters | $12.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Impedimed Ltd
ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue compositi… Read more